66990-30-5
物理化学性质
熔点 | 56-60 °C |
储存条件 | Refrigerator |
溶解度 | DMSO : 100 mg/mL (288.56 mM) |
形态 | Solid |
颜色 | White to off-white |
水溶解性 | Insoluble in water. |
敏感性 | 感光 |
BRN | 1880414 |
CAS 数据库 | 66990-30-5(CAS DataBase Reference) |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H315-H319 |
防范说明 | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
安全说明 | S22-S24/25 |
WGK Germany | 3 |
F | 10-23 |
海关编码 | 29161900 |
知名试剂公司产品信息
常见问题列表
Acyl-CoA oxidase-1 (ACOX1).
10,12-Tricosadiynoic acid-CoA rapidly inhibits ACOX1 activity in a time- and concentration-dependent manner. The activity of ACOX1 decreases by nearly 95% after 5 min of incubation with 10 eq of 10,12-Tricosadiynoic acid-CoA. ACOX1 activity is inhibited only if free 10,12-Tricosadiynoic Acid is activated as the CoA thioester, the substrate form. Inhibition of ACOX1 by 10,12-Tricosadiynoic acid-CoA is irreversible. And the kinetics parameters KI and kinact are calculated to be 680 nm and 3.18 min
−1
, respectively.
10,12-Tricosadiynoic acid is the precursor of 10,12-Tricosadiynoic acid-CoA and is transformed into 10,12-Tricosadiynoic acid-CoA by peroxisomal very long chain acyl-CoA synthetase (VLACS) after entering into cells, and it inhibits ACOX1 in vivo.
10,12-Tricosadiynoic acid (500 nM) inhibits acyl-CoA oxidase-1 (ACOX1) activity. 10,12-Tricosadiynoic acid treatment abrogates the protective effect by Sirt5 siRNA.
10,12-Tricosadiynoic acid (100 μg/kg; oral gavage; daily; for 8 weeks; male Wistar rats) treatment increases hepatic mitochondrial fatty acid oxidation (FAO) via activation of the SIRT1-AMPK (adenosine 5′-monophosphate-activated protein kinase) pathway and proliferator activator receptor α and reduces hydrogen peroxide accumulation in high fat diet-fed rats, which significantly decreases hepatic lipid and ROS contents, reduces body weight gain, and decreases serum triglyceride and insulin levels.
10,12-Tricosadiynoic acid (0 mg/kg, 37.5 mg/kg, 75 mg/kg, and 150 mg/kg diet) treatment does not affect weight gain, but significantly decreases peroxisomal β-oxidation in the liver, and increased body fat accumulation in Nile tilapia. The fish with impaired peroxisomal β-oxidation exhibited higher contents of serum lipid and peroxidation products, and alanine aminotransferase activity, and significantly lowered hepatic activities of superoxide dismutase and catalase.
Animal Model: | Male Wistar rats (210-230 g) fed with high fat diet |
Dosage: | 100 μg/kg |
Administration: | Oral gavage; daily; for 8 weeks |
Result: | Reduced hydrogen peroxide accumulation in high fat diet-fed rats, which significantly decreased hepatic lipid and ROS contents, reduced body weight gain, and decreased serum triglyceride and insulin levels. |